Resmed at SLEEP 2025: Advancing the Future of OSA Diagnosis and Treatment

Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, will attend SLEEP 2025, taking place June 8-11 in Seattle, Washington. 

At the event, Resmed will present new research on the life-saving cardiovascular benefits of CPAP therapy, including how CPAP therapy use is linked to a 22% lower risk of cardiovascular-related emergency room visits or hospitalizations¹. Resmed research will also highlight the impact of CPAP on obstructive sleep apnea (OSA) symptoms and quality of life, the essential role of healthcare providers in supporting patients with OSA, and the increasing and disproportionate burden of OSA among women projected through 2050. In addition, the company will showcase its expanded portfolio of home-based testing solutions designed to simplify and accelerate the path to diagnosis while delivering life-changing health technology that people love. 

SLEEP Research 

Nine Resmed-supported studies will be presented at SLEEP 2025. Research includes:

CPAP Therapy Use Linked to 22% Lower Risk of Cardiovascular-Related Emergency Room Visits or Hospitalizations
-    Study Title: CPAP Therapy Adherence and Cardiovascular-Related Healthcare Utilization
-    Presented by: Fatima Sert, Resmed
-    June 9, 2025, 10:00–11:45 a.m. PT

OSA in Women Set to Surge by 2050
-    Study Title: The Disproportionate Burden of OSA in Women in the United States: A Call for Improved Awareness and Diagnosis
-    Presented by: Elroy Boers, Resmed
-    June 9, 2025, 10:00–11:45 a.m. PT

Patients Perceive Improvements in Quality of Life and Symptoms with CPAP
-    Study Title: CPAP Therapy Associated with Perceived Improvements in Symptoms and Quality of Life in OSA
-    Presented by: Leanne Kaye, Resmed
-    June 9, 2025, 10:00–11:45 a.m. PT

Using AI to Explore Patient Experiences with Healthcare Providers in PAP Therapy
-    Study Title: Harnessing AI to Better Understand Patient Perspectives on the Role of the Healthcare Provider in CPAP Therapy
-    Presented by: Shuying Yu, Resmed 
-    June 9, 2025, 10:00–11:45 a.m. PT 

Industry Product Theater

New Evidence: CPAP Prolongs Life for People Living with OSA

Leading sleep experts will explore the implications of a landmark study published in The Lancet Respiratory Medicine, which demonstrates that CPAP therapy significantly reduces mortality risk in people with OSA. The session will also share clinical insights and examine how evidence-based care and connected technology are reshaping the sleep health landscape to help people breathe and sleep better.

Tuesday, June 10, 11:45 a.m. – 12:45 p.m. PT
Presented by: 
-    Dr. Atul Malhotra, University of California San Diego: Vice Chair of Medicine for Research, Research Chief of Pulmonary, Critical Care and Sleep Medicine at the University of California San Diego School of Medicine and Pulmonologist at UC San Diego Health
-    Dr. Dennis Hwang, Kaiser Permanente: Regional Co-Chair for Sleep Medicine and Director of Regional Sleep Services for Kaiser Permanente Southern California.  Clinical Investigator Recipient, Kaiser Permanente Research and Evaluation. Recipient of AASM’s 2025 Clinical Achievement Award
-    Arturo Garcia, Director of Global Product Marketing, Resmed
-    Moderator: Maureen Crocker, Global Lead, Medical Communications, Resmed 

Resmed’s Innovative Diagnostic Suite at Booth #627

With a full portfolio of diagnostic and treatment solutions on display at Booth #627, attendees are invited to explore how Resmed is helping more people start—and stay—on the path to better sleep and better health. This includes Somnoware™, NightOwl™, and EasyCare Tx 2 titration software bundle designed to streamline workflows, improve diagnostic efficiency, and connect more patients to care.

Resmed is also contributing to the American Academy of Sleep Medicine’s 50th Anniversary Gallery at Booth #541, which will showcase milestones in CPAP innovation, including our legacy masks—highlighting our ongoing commitment to advancing sleep care.

About Resmed  

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com 

*****

¹ O’Hearn A, Kim J, Lin M, et al. Individuals with OSA who use CPAP therapy exhibit lower health care utilization than non-users in a real-world US population. Sleep. 2023;48(Suppl 1):A318. doi:10.1093/sleep/zsad072.844